3530 JOHN HOPKINS COURT, SAN DIEGO, CA
Other Events
Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 million and 246% Unit Growth Since J-code
Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
News, Material Contracts
Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
ImmunityBio Seeks Urgent FDA Meeting on sBLA Submission Guidance Change for NMIBC
Annual Report to Security Holders
Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
S-3ASR
Definitive Information Statement
Preliminary Information Statement
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload